Combined novel tumour-targeted molecular and traditional chemotherapy for treating androgen refractory prostate cancer

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/510238

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

Consistent with Cancer Australia and PCFA priorities, in preclinical studies we will evaluate triple therapy for advanced prostate cancer.The three treatments to be tested together are adenoviruses, gene therapy and docetaxel, each of which has therapeutic potential individually. The combination should increase therapeutic effiacy and decrease the doses required, thus reducing side effects and increasing quality of life. Results obtained should enable translation to a clinical trial.

Funded Activity Details

Start Date: 01-01-2008

End Date: 01-01-2011

Funding Scheme: NHMRC Project Grants

Funding Amount: $551,398.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Gene Therapy

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

Bony metastases | Gene-directed enzyme prodrug therapy (GDEPT) | Hormone refractory prostate cancer | Lung metastases | cancer targeted promoter, Survivin | combined treatment, CRAds, GDEPT + docetaxel | docetaxel | human tissue slices | immunocompetent mice | targeted conditionally replicative adenoviruses (CRAds)

Related Links